Navigation Links
CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
Date:1/31/2008

PALO ALTO, Calif., Jan. 31 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today announced that it will host an Investor Science Day for the financial community in New York City on Thursday, February 7, 2008 beginning at 9:00 a.m. EST.

The event will be webcast live and available for replay on the company's Web site, http://www.cvt.com.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics' clinical and preclinical drug development candidates and programs include regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
2. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
3. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
4. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
5. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
6. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
7. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
8. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
9. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
10. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
11. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... (PRWEB) , ... April 27, 2016 , ... ... Touch screen mobile devices with fingerprint recognition for secure access, voice recognition ... only a few ways consumers are interacting with biometrics technology today. But ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. ... UTHR ) announced today that Martine ... United Therapeutics will provide an overview and update on ... Annual Health Care Conference. The presentation ... 10:00 a.m. Eastern Time, and can be accessed via ...
(Date:4/27/2016)... ... April 27, 2016 , ... NDA Partners Chairman Carl ... an Expert Consultant. Mr. Clark was formerly a Vice President with US ... small molecule monographs based on analytical methods. NDA Partners Expert Consultants are ...
(Date:4/27/2016)... ... April 27, 2016 , ... ... PET (Positron Emission Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI ... testing novel treatments in small animal subjects. Simultaneous PET/MRI imaging offers a solution ...
Breaking Biology Technology:
(Date:3/11/2016)... 2016 --> ... "Image Recognition Market by Technology (Pattern Recognition), by Component ... Deployment Type (On-Premises and Cloud), by Industry Vertical and ... MarketsandMarkets, the global market is expected to grow from ... by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... 2016 This BCC Research report provides an ... RNA Sequencing (RNA Seq) market for the years 2015, ... and reagents, data analysis, and services. Use ... RNA-Sequencing market such as RNA-Sequencing tools and reagents, RNA-Sequencing ... affecting each segment and forecast their market growth, future ...
(Date:3/8/2016)... RALEIGH, N.C. , March 8, 2016 /PRNewswire/ ... biometric sensor technology, today announced it has secured ... led by GII Tech, a new venture fund ... LLC, with additional participation from existing investors TDF ... use the funds to continue its triple-digit growth ...
Breaking Biology News(10 mins):